Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia

Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. He...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2024-11, Vol.60 (11), p.1782
Main Authors: Ayabe, Kengo, Komiyama, Tomoyoshi, Takekawa, Hiroyuki, Kang, Honsa, Tsumagari, Yasuaki, Ito, Miwa, Ashikaga, Keiichi, Shibata, Yoshisato
Format: Article
Language:English
Subjects:
Ablation
Aged
Anti-Arrhythmia Agents - pharmacology
Anti-Arrhythmia Agents - therapeutic use
Atrial fibrillation
Atrial Fibrillation - drug therapy
Atrial Fibrillation - physiopathology
Blood pressure
Brief Report
Cardiac arrhythmia
Cardiovascular disease
Care and treatment
Catheters
Cost analysis
Ejection fraction
Female
Heart
Heart beat
Heart Failure - complications
Heart Failure - drug therapy
Heart Failure - physiopathology
Heart Rate - drug effects
Heart surgery
Hemoglobin
HFmrEF
HFpEF
HFrEF
Humans
landiolol
Male
Middle Aged
Morpholines - pharmacology
Morpholines - therapeutic use
Mortality
Paroxysmal tachycardia
Patients
Sinuses
Tachycardia - drug therapy
Tachycardia - physiopathology
Treatment Outcome
Urea - administration & dosage
Urea - analogs & derivatives
Urea - pharmacology
Urea - therapeutic use
Vital signs
β-blocker
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. Hence, this study aimed to evaluate the effectiveness of landiolol in patients with atrial fibrillation (AF) and atrial tachycardia (AT), not limited to those with heart failure with a reduced ejection fraction. To this end, we evaluated the efficacy and safety of landiolol in managing tachycardiac AF and tachycardiac atrial flutter/AT in 44 patients with reduced left ventricular function. We found that while landiolol was effective in managing patients with AF and heart failure with a preserved or mid-range ejection fraction, however, it might be more challenging to control heart rate in patients with AT using a similar dosage of landiolol.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina60111782